# Novartis receives FDA approval for new radioligand therapy facility in Indianapolis

Novartis announced FDA approval for commercial manufacturing of Pluvicto at its new 70,000-square foot radioligand therapy manufacturing facility in Indianapolis, Indiana. The facility is the company's largest and most advanced RLT site, increasing production capacity to 250,000 doses in 2024.

- Type: Expansion
- Announced: 2024-01-05
- Where: Indianapolis, Indiana, United States
- Starts operating: 5 Jan 2024
- Status: completed
- Capacity: 250,000 doses per year
- Products: Pluvicto, Lutathera, radioligand therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md)

## Sources

- [novartis.com](https://www.novartis.com/news/media-releases/novartis-expands-production-pluvictotm-addition-its-largest-and-most-advanced-radioligand-therapy-manufacturing-facility-indianapolis), 2024-01-05: "Adding a second US RLT facility, our largest and most advanced yet, into our manufacturing network underscores our commitment to ensure a consistent and reliable experience for patients"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.